Overview

DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer

Status:
Recruiting

Trial end date:
2026-12-15

Target enrollment:

Participant gender:

Summary

A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)

Phase:

Phase 2

Details

Lead Sponsor:

Criterium, Inc.

Treatments:

Fulvestrant
Palbociclib